Support

The Next Generation in Bone Health

Our mission is to provide the world medical community with the very first radiation-free and portable solution for the early diagnosis of osteoporosis.

About Echolight

Echolight Medical was established in Italy with our head office in Lecce, and in 2020 opened offices in the United States. Since then, our sales network has grown to more than 40 distributors and several hundreds of satisfied customers across the world who have adopted the innovative REMS technology for assessing the bone condition of their patients.

Created as a spin-off of the Italian National Research Council, Echolight is at the forefront of medical innovation, introducing new cutting-edge solutions to contribute to human wellbeing. We’ve been awarded all the standard certificates: UNI CEI EN ISO 13485: 2016, Quality Management System UNI EN ISO 9001: 2015, CE mark, FDA clearance, and other major certificates worldwide for innovative solutions considered as the best practice in bone health for personalized medicine.

Today, we envision a future where advanced, non-invasive diagnostics empower earlier detection, more personalized treatment, and better long-term health outcomes. By continuing to push the boundaries of ultrasound-based innovation, we aim to make bone and body composition assessment accessible to every clinician and patient, around the world.

Company Timeline

2010
Start

Echolight srl was officially incorporated by the founding team with a revolutionary idea: developing the first radiation-free device for early diagnosis of osteoporosis at the lumbar vertebrae and the femoral neck.

2011
Patent

The first patent for R.E.M.S. technology is officially filed. An innovative ultrasound-based approach for characterizing bone microarchitecture.

Life Science Capital

Life Science Capital S.p.a., an Italian investment company in the medical device sector, invests in Echolight to support and speed up the research and development activities of the company.

2012
EchoS

The first version of Echos is finalized: the only radiation free device for bone densitometry at the lumbar vertebrae and the femoral neck. A decisive step towards a new era in the early diagnosis of osteoporosis and bone health assessment.

2013
Clinical Trials

In collaboration with the National Council of Research the first multi-center study for the clinical validation of R.E.M.S. technology in the most important reference centers for the diagnosis of osteoporosis is launched.

2014
Certifications

Echolight obtains all standard certifications: UNI CEI EN ISO 13485:2012, ISO 13485:2003, UNI EN ISO 9001:2008 Quality Management System, and the CE mark for EchoS, EchoStation, and EchoStudio from KIWA CERMET.

2015
Premier

Echolight introduces to the international medical community the latest release of Echos at the World Congress of Osteoporosis.

2016
Round A

Panakès and Invitalia Ventures have co-led an investment round in Echolight, in order to support the clinical validation of the innovative technology and the worldwide launch of the product.

2017
Advisory Board

Echolight established the new international scientific advisory board with the most important medical personalities in the diagnosis of osteoporosis.

Market Launch

Echolight at the International Trade Fair MEDICA launched Echos after extensive research and development activities carried out over the last eight years.

2018
FDA Clearance

Echolight S.p.A. has received 510(k) clearance from the Food and Drug Administration (FDA) to market its range of products in the U.S.A.

Multicenter Study

Milestone publication on Osteoporosis International about R.E.M.S. Multicenter Clinical Trial: “Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck.

2019
Consensus Paper

Echolight obtained a Consensus Paper from ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, on R.E.M.S. technology.

Expansion

Echolight in less than three years has a sales network of 40 distributors and several hundred satisfied customers all over the world.

2020
Echolight USA

Echolight announces the opening of a new corporate headquarters in the United States located in Seattle (since moved to Houston, TX).

2021
REMS in the Guidelines

REMS technology recommended in the guidelines for fragility fractures risk assessment.

2023
CPT Code

Echolight is assigned a CPT code for the reimbursement of bone evaluation using REMS technology.

Echolight Around the Globe

The Echolight network has expanded across the world with physicians and wellness centers who have adopted our innovative REMS technology for assessing the bone condition of their patients.

See bone health in a new light

Discover how radiation-free, portable REMS technology can improve patient outcomes and streamline osteoporosis care.

Talk to the Team
Contact Us